Hansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory…

Read MoreHansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Update Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls

In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since…

Read MoreUpdate Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls

Neurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability

A recent comprehensive study, published in The Lancet Neurology, has revealed staggering figures regarding neurological conditions worldwide. In 2021, over 3 billion individuals were found to be living with such…

Read MoreNeurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability

Ionis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment

Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study,…

Read MoreIonis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment